{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:51:57Z","timestamp":1794487917739,"version":"4.9.1"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T00:00:00Z","timestamp":1521158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","award":["15OKG16"],"award-info":[{"award-number":["15OKG16"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00467-018-3929-z","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T07:59:57Z","timestamp":1521187197000},"page":"389-403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome"],"prefix":"10.1007","volume":"34","author":[{"given":"Anne M.","family":"Schijvens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia N.","family":"de Wildt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel F.","family":"Schreuder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,16]]},"reference":[{"key":"3929_CR1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00467-011-1851-8","volume":"26","author":"L Bakkali El","year":"2011","unstructured":"El Bakkali L, Rodrigues Pereira R, Kuik DJ, Ket JC, van Wijk JA (2011) Nephrotic syndrome in the Netherlands: a population-based cohort study and a review of the literature. Pediatr Nephrol 26:1241\u20131246","journal-title":"Pediatr Nephrol"},{"key":"3929_CR2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1681\/ASN.V85769","volume":"8","author":"P Tarshish","year":"1997","unstructured":"Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr (1997) Prognostic significance of the early course of minimal change nephrotic syndrome: report of the international study of kidney disease in children. J Am Soc Nephrol 8:769\u2013776","journal-title":"J Am Soc Nephrol"},{"key":"3929_CR3","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group (2012) KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2:139\u2013274"},{"key":"3929_CR4","doi-asserted-by":"crossref","first-page":"E424","DOI":"10.9778\/cmajo.20160078","volume":"5","author":"SM Samuel","year":"2017","unstructured":"Samuel SM, Flynn R, Zappitelli M, Dart A, Parekh R, Pinsk M, Mammen C, Wade A, Scott SD, Canadian Childhood Nephrotic Syndrome Project T (2017) Factors influencing practice variation in the management of nephrotic syndrome: a qualitative study of pediatric nephrology care providers. CMAJ Open 5:E424\u2013E430","journal-title":"CMAJ Open"},{"key":"3929_CR5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1681\/ASN.2012070646","volume":"24","author":"N Teeninga","year":"2013","unstructured":"Teeninga N, Kist-van Holthe JE, van Rijswijk N, de Mos NI, Hop WC, Wetzels JF, van der Heijden AJ, Nauta J (2013) Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J Am Soc Nephrol 24:149\u2013159","journal-title":"J Am Soc Nephrol"},{"key":"3929_CR6","unstructured":"Webb N, Wooley R, Brettell E, Cummins C, Trompeter R, Barsoum E, Ives N (2017) Standard vs. extended course prednisolone therapy for the presenting episode of steroid sensitive nephrotic syndrome: the PREDNOS study. (abstract) ESPN 50th annual meeting"},{"key":"3929_CR7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018148","volume":"7","author":"AM Schijvens","year":"2017","unstructured":"Schijvens AM, Dorresteijn EM, Roeleveld N, Ter Heine R, van Wijk JAE, Bouts AHM, Keijzer-Veen MG, van de Kar N, van den Heuvel L, Schreuder MF (2017) REducing STEroids in Relapsing Nephrotic syndrome: the RESTERN study\u2014protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study. BMJ Open 7:e018148","journal-title":"BMJ Open"},{"key":"3929_CR8","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/ndt\/gfu363","volume":"30","author":"MA Saleem","year":"2015","unstructured":"Saleem MA (2015) One hundred ways to kill a podocyte. Nephrol Dial Transplant 30:1266\u20131271","journal-title":"Nephrol Dial Transplant"},{"key":"3929_CR9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2215\/CJN.05000516","volume":"12","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli M, Massella L, Ruggiero B, Emma F (2017) Minimal change disease. Clin J Am Soc Nephrol 12:332\u2013345","journal-title":"Clin J Am Soc Nephrol"},{"key":"3929_CR10","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.kint.2016.10.013","volume":"91","author":"A Bierzynska","year":"2017","unstructured":"Bierzynska A, McCarthy HJ, Soderquest K, Sen ES, Colby E, Ding WY, Nabhan MM, Kerecuk L, Hegde S, Hughes D, Marks S, Feather S, Jones C, Webb NJ, Ognjanovic M, Christian M, Gilbert RD, Sinha MD, Lord GM, Simpson M, Koziell AB, Welsh GI, Saleem MA (2017) Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management. Kidney Int 91:937\u2013947","journal-title":"Kidney Int"},{"key":"3929_CR11","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1056\/NEJMc1202500","volume":"366","author":"L Gallon","year":"2012","unstructured":"Gallon L, Leventhal J, Skaro A, Kanwar Y, Alvarado A (2012) Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med 366:1648\u20131649","journal-title":"N Engl J Med"},{"key":"3929_CR12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.12688\/f1000research.10165.1","volume":"6","author":"A Bierzynska","year":"2017","unstructured":"Bierzynska A, Saleem M (2017) Recent advances in understanding and treating nephrotic syndrome. F1000Res 6:121","journal-title":"F1000Res"},{"key":"3929_CR13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/ckj\/sfv090","volume":"8","author":"T Wada","year":"2015","unstructured":"Wada T, Nangaku M (2015) A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues. Clin Kidney J 8:708\u2013715","journal-title":"Clin Kidney J"},{"key":"3929_CR14","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00467-011-1947-1","volume":"27","author":"V Elie","year":"2012","unstructured":"Elie V, Fakhoury M, Deschenes G, Jacqz-Aigrain E (2012) Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives. Pediatr Nephrol 27:1249\u20131256","journal-title":"Pediatr Nephrol"},{"key":"3929_CR15","doi-asserted-by":"crossref","unstructured":"(1978) Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 13:159\u2013165","DOI":"10.1038\/ki.1978.23"},{"key":"3929_CR16","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrd1497","volume":"3","author":"R Weinshilboum","year":"2004","unstructured":"Weinshilboum R, Wang L (2004) Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 3:739\u2013748","journal-title":"Nat Rev Drug Discov"},{"key":"3929_CR17","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","volume":"348","author":"WE Evans","year":"2003","unstructured":"Evans WE, McLeod HL (2003) Pharmacogenomics\u2014drug disposition, drug targets, and side effects. N Engl J Med 348:538\u2013549","journal-title":"N Engl J Med"},{"key":"3929_CR18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra020021","volume":"348","author":"R Weinshilboum","year":"2003","unstructured":"Weinshilboum R (2003) Inheritance and drug response. N Engl J Med 348:529\u2013537","journal-title":"N Engl J Med"},{"key":"3929_CR19","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2217\/pgs.15.101","volume":"16","author":"E Cuzzoni","year":"2015","unstructured":"Cuzzoni E, De Iudicibus S, Franca R, Stocco G, Lucafo M, Pelin M, Favretto D, Pasini A, Montini G, Decorti G (2015) Glucocorticoid pharmacogenetics in pediatric idiopathic nephrotic syndrome. Pharmacogenomics 16:1631\u20131648","journal-title":"Pharmacogenomics"},{"key":"3929_CR20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","volume":"44","author":"D Czock","year":"2005","unstructured":"Czock D, Keller F, Rasche FM, Haussler U (2005) Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44:61\u201398","journal-title":"Clin Pharmacokinet"},{"key":"3929_CR21","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/jps.2600751013","volume":"75","author":"M Ponec","year":"1986","unstructured":"Ponec M, Kempenaar J, Shroot B, Caron JC (1986) Glucocorticoids: binding affinity and lipophilicity. J Pharm Sci 75:973\u2013975","journal-title":"J Pharm Sci"},{"key":"3929_CR22","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.cell.2014.04.038","volume":"157","author":"E Kirschke","year":"2014","unstructured":"Kirschke E, Goswami D, Southworth D, Griffin PR, Agard DA (2014) Glucocorticoid receptor function regulated by coordinated action of the Hsp90 and Hsp70 chaperone cycles. Cell 157:1685\u20131697","journal-title":"Cell"},{"key":"3929_CR23","first-page":"145","volume":"2","author":"DN Payne","year":"2001","unstructured":"Payne DN, Adcock IM (2001) Molecular mechanisms of corticosteroid actions. Paediatr Respir Rev 2:145\u2013150","journal-title":"Paediatr Respir Rev"},{"key":"3929_CR24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jsbmb.2010.02.018","volume":"120","author":"PJ Barnes","year":"2010","unstructured":"Barnes PJ (2010) Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 120:76\u201385","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3929_CR25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1006\/pupt.2000.0243","volume":"13","author":"IM Adcock","year":"2000","unstructured":"Adcock IM (2000) Molecular mechanisms of glucocorticosteroid actions. Pulm Pharmacol Ther 13:115\u2013126","journal-title":"Pulm Pharmacol Ther"},{"key":"3929_CR26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1042\/bst0310060","volume":"31","author":"M Kagoshima","year":"2003","unstructured":"Kagoshima M, Ito K, Cosio B, Adcock IM (2003) Glucocorticoid suppression of nuclear factor-kappa B: a role for histone modifications. Biochem Soc Trans 31:60\u201365","journal-title":"Biochem Soc Trans"},{"key":"3929_CR27","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.steroids.2007.12.002","volume":"73","author":"M Lowenberg","year":"2008","unstructured":"Lowenberg M, Stahn C, Hommes DW, Buttgereit F (2008) Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 73:1025\u20131029","journal-title":"Steroids"},{"key":"3929_CR28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4103\/1817-1737.65040","volume":"5","author":"AA Alangari","year":"2010","unstructured":"Alangari AA (2010) Genomic and non-genomic actions of glucocorticoids in asthma. Ann Thorac Med 5:133\u2013139","journal-title":"Ann Thorac Med"},{"key":"3929_CR29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.bjp.0703272","volume":"130","author":"JD Croxtall","year":"2000","unstructured":"Croxtall JD, Choudhury Q, Flower RJ (2000) Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol 130:289\u2013298","journal-title":"Br J Pharmacol"},{"key":"3929_CR30","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/BF00869822","volume":"4","author":"M Rostin","year":"1990","unstructured":"Rostin M, Barthe P, Houin G, Alvinerie M, Bouissou F (1990) Pharmacokinetics of prednisolone in children with the nephrotic syndrome. Pediatr Nephrol 4:470\u2013473","journal-title":"Pediatr Nephrol"},{"key":"3929_CR31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2125.1984.tb02367.x","volume":"17","author":"G Gatti","year":"1984","unstructured":"Gatti G, Perucca E, Frigo GM, Notarangelo LD, Barberis L, Martini A (1984) Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. Br J Clin Pharmacol 17:423\u2013431","journal-title":"Br J Clin Pharmacol"},{"key":"3929_CR32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF01060885","volume":"9","author":"JQ Rose","year":"1981","unstructured":"Rose JQ, Yurchak AM, Jusko WJ (1981) Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm 9:389\u2013417","journal-title":"J Pharmacokinet Biopharm"},{"key":"3929_CR33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0022-3476(78)80529-0","volume":"93","author":"OC Green","year":"1978","unstructured":"Green OC, Winter RJ, Kawahara FS, Phillips LS, Lewy PR, Hart RL, Pachman LM (1978) Plasma levels, half-life values, and correlation with physiologic assays for growth and immunity. J Pediatr 93:299\u2013303","journal-title":"J Pediatr"},{"key":"3929_CR34","first-page":"159","volume":"3","author":"ML Rocci Jr","year":"1982","unstructured":"Rocci ML Jr, Assael BM, Appiani AC, Edefonti A, Jusko WJ (1982) Effect on nephrotic syndrome on absorption and disposition of prednisolone in children. Int J Pediatr Nephrol 3:159\u2013166","journal-title":"Int J Pediatr Nephrol"},{"key":"3929_CR35","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2165\/00003088-199019020-00003","volume":"19","author":"BM Frey","year":"1990","unstructured":"Frey BM, Frey FJ (1990) Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 19:126\u2013146","journal-title":"Clin Pharmacokinet"},{"key":"3929_CR36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-197904020-00004","volume":"4","author":"ME Pickup","year":"1979","unstructured":"Pickup ME (1979) Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 4:111\u2013128","journal-title":"Clin Pharmacokinet"},{"key":"3929_CR37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0272-6386(84)80081-5","volume":"3","author":"FJ Frey","year":"1984","unstructured":"Frey FJ, Frey BM (1984) Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. Am J Kidney Dis 3:339\u2013348","journal-title":"Am J Kidney Dis"},{"key":"3929_CR38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000182800","volume":"32","author":"FJ Frey","year":"1982","unstructured":"Frey FJ, Frey BM (1982) Altered prednisolone kinetics in patients with the nephrotic syndrome. Nephron 32:45\u201348","journal-title":"Nephron"},{"key":"3929_CR39","volume-title":"Drug prescribing in renal failure","author":"WM Bennett","year":"1994","unstructured":"Bennett WM, Aronoff GR, Golper TA, Pulliam J, Wolfson M, Singer I (1994) Drug prescribing in renal failure. American College of Physicians, Philadelphia"},{"key":"3929_CR40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/adc.65.2.196","volume":"65","author":"PF Miller","year":"1990","unstructured":"Miller PF, Bowmer CJ, Wheeldon J, Brocklebank JT (1990) Pharmacokinetics of prednisolone in children with nephrosis. Arch Dis Child 65:196\u2013200","journal-title":"Arch Dis Child"},{"key":"3929_CR41","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/FTD.0000000000000308","volume":"38","author":"N Teeninga","year":"2016","unstructured":"Teeninga N, Guan Z, Stevens J, Kist-van Holthe JE, Ackermans MT, van der Heijden AJ, van Schaik RH, van Gelder T, Nauta J (2016) Population pharmacokinetics of prednisolone in relation to clinical outcome in children with nephrotic syndrome. Ther Drug Monit 38:534\u2013545","journal-title":"Ther Drug Monit"},{"key":"3929_CR42","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/ki.1983.110","volume":"23","author":"H Bergrem","year":"1983","unstructured":"Bergrem H (1983) Pharmacokinetics and protein binding of prednisolone in patients with nephrotic syndrome and patients undergoing hemodialysis. Kidney Int 23:876\u2013881","journal-title":"Kidney Int"},{"key":"3929_CR43","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1172\/JCI108035","volume":"55","author":"R Gugler","year":"1975","unstructured":"Gugler R, Shoeman DW, Huffman DH, Cohlmia JB, Azarnoff DL (1975) Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest 55:1182\u20131189","journal-title":"J Clin Invest"},{"key":"3929_CR44","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1210\/jc.2002-020970","volume":"87","author":"S Diederich","year":"2002","unstructured":"Diederich S, Eigendorff E, Burkhardt P, Quinkler M, Bumke-Vogt C, Rochel M, Seidelmann D, Esperling P, Oelkers W, Bahr V (2002) 11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab 87:5695\u20135701","journal-title":"J Clin Endocrinol Metab"},{"key":"3929_CR45","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/clpt.1989.42","volume":"45","author":"RM Zurcher","year":"1989","unstructured":"Zurcher RM, Frey BM, Frey FJ (1989) Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther 45:366\u2013372","journal-title":"Clin Pharmacol Ther"},{"key":"3929_CR46","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00315399","volume":"45","author":"KH Lee","year":"1993","unstructured":"Lee KH, Shin JG, Chong WS, Kim S, Lee JS, Jang IJ, Shin SG (1993) Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. Eur J Clin Pharmacol 45:287\u2013289","journal-title":"Eur J Clin Pharmacol"},{"key":"3929_CR47","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/clpt.1987.173","volume":"42","author":"M Bartoszek","year":"1987","unstructured":"Bartoszek M, Brenner AM, Szefler SJ (1987) Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. Clin Pharmacol Ther 42:424\u2013432","journal-title":"Clin Pharmacol Ther"},{"key":"3929_CR48","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40262-012-0007-8","volume":"51","author":"TK Bergmann","year":"2012","unstructured":"Bergmann TK, Barraclough KA, Lee KJ, Staatz CE (2012) Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. Clin Pharmacokinet 51:711\u2013741","journal-title":"Clin Pharmacokinet"},{"key":"3929_CR49","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/00007890-198704000-00007","volume":"43","author":"FJ Frey","year":"1987","unstructured":"Frey FJ, Schnetzer A, Horber FF, Frey BM (1987) Evidence that cyclosporine does not affect the metabolism of prednisolone after renal transplantation. Transplantation 43:494\u2013498","journal-title":"Transplantation"},{"key":"3929_CR50","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s004670050344","volume":"11","author":"BK Ekka","year":"1997","unstructured":"Ekka BK, Bagga A, Srivastava RN (1997) Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatr Nephrol 11:597\u2013599","journal-title":"Pediatr Nephrol"},{"key":"3929_CR51","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1248\/bpb.26.510","volume":"26","author":"T Usui","year":"2003","unstructured":"Usui T, Saitoh Y, Komada F (2003) Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull 26:510\u2013517","journal-title":"Biol Pharm Bull"},{"key":"3929_CR52","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1097\/00007890-200211270-00014","volume":"74","author":"T Shimada","year":"2002","unstructured":"Shimada T, Terada A, Yokogawa K, Kaneko H, Nomura M, Kaji K, Kaneko S, Kobayashi K, Miyamoto K (2002) Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation 74:1419\u20131424","journal-title":"Transplantation"},{"key":"3929_CR53","first-page":"27","volume":"7","author":"ML Amin","year":"2013","unstructured":"Amin ML (2013) P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7:27\u201334","journal-title":"Drug Target Insights"},{"key":"3929_CR54","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1210\/edrv-17-3-245","volume":"17","author":"CM Bamberger","year":"1996","unstructured":"Bamberger CM, Schulte HM, Chrousos GP (1996) Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 17:245\u2013261","journal-title":"Endocr Rev"},{"key":"3929_CR55","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cpt.372","volume":"100","author":"E Cuzzoni","year":"2016","unstructured":"Cuzzoni E, De Iudicibus S, Stocco G, Favretto D, Pelin M, Messina G, Ghio L, Monti E, Pasini A, Montini G, Decorti G (2016) In vitro sensitivity to methyl-prednisolone is associated with clinical response in pediatric idiopathic nephrotic syndrome. Clini Pharm Ther 100:268\u2013274","journal-title":"Clini Pharm Ther"},{"key":"3929_CR56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2007.05.019","volume":"275","author":"C Stahn","year":"2007","unstructured":"Stahn C, Lowenberg M, Hommes DW, Buttgereit F (2007) Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 275:71\u201378","journal-title":"Mol Cell Endocrinol"},{"key":"3929_CR57","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","volume":"362","author":"AA Eddy","year":"2003","unstructured":"Eddy AA, Symons JM (2003) Nephrotic syndrome in childhood. Lancet 362:629\u2013639","journal-title":"Lancet"},{"key":"3929_CR58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1046\/j.1523-1755.1999.00503.x","volume":"56","author":"K Yan","year":"1999","unstructured":"Yan K, Kudo A, Hirano H, Watanabe T, Tasaka T, Kataoka S, Nakajima N, Nishibori Y, Shibata T, Kohsaka T, Higashihara E, Tanaka H, Watanabe H, Nagasawa T, Awa S (1999) Subcellular localization of glucocorticoid receptor protein in the human kidney glomerulus. Kidney Int 56:65\u201373","journal-title":"Kidney Int"},{"key":"3929_CR59","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/sj.ki.5001655","volume":"70","author":"CY Xing","year":"2006","unstructured":"Xing CY, Saleem MA, Coward RJ, Ni L, Witherden IR, Mathieson PW (2006) Direct effects of dexamethasone on human podocytes. Kidney Int 70:1038\u20131045","journal-title":"Kidney Int"},{"key":"3929_CR60","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1111\/j.1523-1755.2005.00723.x","volume":"68","author":"RF Ransom","year":"2005","unstructured":"Ransom RF, Lam NG, Hallett MA, Atkinson SJ, Smoyer WE (2005) Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int 68:2473\u20132483","journal-title":"Kidney Int"},{"key":"3929_CR61","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1681\/ASN.2005020142","volume":"16","author":"T Wada","year":"2005","unstructured":"Wada T, Pippin JW, Marshall CB, Griffin SV, Shankland SJ (2005) Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. J Am Soc Nephrol 16:2615\u20132625","journal-title":"J Am Soc Nephrol"},{"key":"3929_CR62","doi-asserted-by":"crossref","first-page":"F845","DOI":"10.1152\/ajprenal.00161.2010","volume":"299","author":"A Guess","year":"2010","unstructured":"Guess A, Agrawal S, Wei CC, Ransom RF, Benndorf R, Smoyer WE (2010) Dose- and time-dependent glucocorticoid receptor signaling in podocytes. Am J Physiol - Renal Physiol 299:F845\u2013F853","journal-title":"Am J Physiol - Renal Physiol"},{"key":"3929_CR63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/15513815.2016.1225872","volume":"36","author":"Y Gamal","year":"2017","unstructured":"Gamal Y, Badawy A, Swelam S, Tawfeek MS, Gad EF (2017) Glomerular glucocorticoid receptors expression and clinicopathological types of childhood nephrotic syndrome. Fetal Pediatr Pathol 36:16\u201326","journal-title":"Fetal Pediatr Pathol"},{"issue":"Suppl 2","key":"3929_CR64","first-page":"ii10","volume":"52","author":"WE Evans","year":"2003","unstructured":"Evans WE (2003) Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut 52(Suppl 2):ii10\u2013ii18","journal-title":"Gut"},{"key":"3929_CR65","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/17425255.2017.1395413","volume":"13","author":"LM Andrews","year":"2017","unstructured":"Andrews LM, Li Y, De Winter BCM, Shi YY, Baan CC, Van Gelder T, Hesselink DA (2017) Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. Expert Opin Drug Metab Toxicol 13:1225\u20131236","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3929_CR66","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2217\/pgs.13.52","volume":"14","author":"JA Johnson","year":"2013","unstructured":"Johnson JA (2013) Pharmacogenetics in clinical practice: how far have we come and where are we going? Pharmacogenomics 14:835\u2013843","journal-title":"Pharmacogenomics"},{"key":"3929_CR67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrg.2016.12","volume":"17","author":"MR Nelson","year":"2016","unstructured":"Nelson MR, Johnson T, Warren L, Hughes AR, Chissoe SL, Xu CF, Waterworth DM (2016) The genetics of drug efficacy: opportunities and challenges. Nat Rev Genet 17:197\u2013206","journal-title":"Nat Rev Genet"},{"key":"3929_CR68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","volume":"98","author":"KA Birdwell","year":"2015","unstructured":"Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, Leeder JS, van Schaik R, Thummel KE, Klein TE, Caudle KE, MacPhee IA (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther 98:19\u201324","journal-title":"Clin Pharmacol Ther"},{"key":"3929_CR69","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/ki.2013.531","volume":"85","author":"N Teeninga","year":"2014","unstructured":"Teeninga N, Kist-van Holthe JE, van den Akker EL, Kersten MC, Boersma E, Krabbe HG, Knoers NV, van der Heijden AJ, Koper JW, Nauta J (2014) Genetic and in vivo determinants of glucocorticoid sensitivity in relation to clinical outcome of childhood nephrotic syndrome. Kidney Int 85:1444\u20131453","journal-title":"Kidney Int"},{"key":"3929_CR70","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00467-008-0772-7","volume":"23","author":"G Zalewski","year":"2008","unstructured":"Zalewski G, Wasilewska A, Zoch-Zwierz W, Chyczewski L (2008) Response to prednisone in relation to NR3C1 intron B polymorphisms in childhood nephrotic syndrome. Pediatr Nephrol 23:1073\u20131078","journal-title":"Pediatr Nephrol"},{"key":"3929_CR71","doi-asserted-by":"crossref","first-page":"1417456","DOI":"10.1155\/2016\/1417456","volume":"2016","author":"M Suvanto","year":"2016","unstructured":"Suvanto M, Jahnukainen T, Kestila M, Jalanko H (2016) Single nucleotide polymorphisms in pediatric idiopathic nephrotic syndrome. Int J Nephrol 2016:1417456","journal-title":"Int J Nephrol"},{"key":"3929_CR72","doi-asserted-by":"publisher","unstructured":"Liu J, Wan Z, Song Q, Li Z, He Y, Tang Y, Xie W, Xie Y, Zhang J (2017) NR3C1 gene polymorphisms are associated with steroid resistance in patients with primary nephrotic syndrome. Pharmacogenomics. https:\/\/doi.org\/10.2217\/pgs-2017-0084","DOI":"10.2217\/pgs-2017-0084"},{"key":"3929_CR73","doi-asserted-by":"crossref","first-page":"338","DOI":"10.5414\/CN109126","volume":"88","author":"N Du","year":"2017","unstructured":"Du N, Yang F, Li L, Liu X, Sun L, Zhang S, He X, Tang Y, Shi J, Liu C, Zhang X (2017) Association of single-nucleotide polymorphism in the FKBP5 gene with response to steroids in pediatric patients with primary nephrotic syndrome. Clin Nephrol 88:338\u2013343","journal-title":"Clin Nephrol"},{"key":"3929_CR74","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0272-6386(03)00652-8","volume":"42","author":"Y Kobayashi","year":"2003","unstructured":"Kobayashi Y, Arakawa H, Suzuki M, Takizawa T, Tokuyama K, Morikawa A (2003) Polymorphisms of interleukin-4-related genes in Japanese children with minimal change nephrotic syndrome. Am J Kidney Dis 42:271\u2013276","journal-title":"Am J Kidney Dis"},{"key":"3929_CR75","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s12291-011-0126-2","volume":"26","author":"T Jafar","year":"2011","unstructured":"Jafar T, Agrawal S, Mahdi AA, Sharma RK, Awasthi S, Agarwal GG (2011) Cytokine gene polymorphism in idiopathic nephrotic syndrome children. Indian J Clin Biochem 26:296\u2013302","journal-title":"Indian J Clin Biochem"},{"key":"3929_CR76","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4103\/0019-5359.44017","volume":"62","author":"G Tripathi","year":"2008","unstructured":"Tripathi G, Jafar T, Mandal K, Mahdi AA, Awasthi S, Sharma RK, Kumar A, Gulati S, Agrawal S (2008) Does cytokine gene polymorphism affect steroid responses in idiopathic nephrotic syndrome? Indian J Med Sci 62:383\u2013391","journal-title":"Indian J Med Sci"},{"key":"3929_CR77","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00467-008-1003-y","volume":"24","author":"Y Ikeuchi","year":"2009","unstructured":"Ikeuchi Y, Kobayashi Y, Arakawa H, Suzuki M, Tamra K, Morikawa A (2009) Polymorphisms in interleukin-4-related genes in patients with minimal change nephrotic syndrome. Pediatr Nephrol 24:489\u2013495","journal-title":"Pediatr Nephrol"},{"key":"3929_CR78","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1093\/ndt\/gfn395","volume":"23","author":"J M\u00fcller-Berghaus","year":"2008","unstructured":"M\u00fcller-Berghaus J, Kemper MJ, Hoppe B, Querfeld U, M\u00fcller-Wiefel DE, Morahan G, Schadendorf D, Tenbrock K (2008) The clinical course of steroid-sensitive childhood nephrotic syndrome is associated with a functional IL12B promoter polymorphism. Nephrol Dial Transplant 23:3841\u20133844","journal-title":"Nephrol Dial Transplant"},{"key":"3929_CR79","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00467-005-1930-9","volume":"20","author":"A Berdeli","year":"2005","unstructured":"Berdeli A, Mir S, Ozkayin N, Serdaroglu E, Tabel Y, Cura A (2005) Association of macrophage migration inhibitory factor -173C allele polymorphism with steroid resistance in children with nephrotic syndrome. Pediatr Nephrol 20:1566\u20131571","journal-title":"Pediatr Nephrol"},{"key":"3929_CR80","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00467-007-0729-2","volume":"23","author":"M Vivarelli","year":"2008","unstructured":"Vivarelli M, D\u2019Urbano LE, Stringini G, Ghiggeri GM, Caridi G, Donn R, Tozzi A, Emma F, De Benedetti F (2008) Association of the macrophage migration inhibitory factor -173*C allele with childhood nephrotic syndrome. Pediatr Nephrol 23:743\u2013748","journal-title":"Pediatr Nephrol"},{"key":"3929_CR81","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1017\/S2040174415007850","volume":"7","author":"OR Ramayani","year":"2016","unstructured":"Ramayani OR, Sekarwana N, Trihono PP, Sadewa AH, Lelo A (2016) A genetic study of steroid-resistant nephrotic syndrome: relationship between polymorphism -173 G to C in the MIF gene and serum level MIF in children. J Dev Orig Health Dis 7:102\u2013107","journal-title":"J Dev Orig Health Dis"},{"key":"3929_CR82","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00467-006-0275-3","volume":"22","author":"A Wasilewska","year":"2007","unstructured":"Wasilewska A, Zalewski G, Chyczewski L, Zoch-Zwierz W (2007) MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children. Pediatr Nephrol 22:44\u201351","journal-title":"Pediatr Nephrol"},{"key":"3929_CR83","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00467-012-2182-0","volume":"27","author":"YH Chiou","year":"2012","unstructured":"Chiou YH, Wang LY, Wang TH, Huang SP (2012) Genetic polymorphisms influence the steroid treatment of children with idiopathic nephrotic syndrome. Pediatr Nephrol 27:1511\u20131517","journal-title":"Pediatr Nephrol"},{"key":"3929_CR84","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.gene.2013.08.045","volume":"530","author":"DM Youssef","year":"2013","unstructured":"Youssef DM, Attia TA, El-Shal AS, Abduelometty FA (2013) Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome: impact on susceptibility and response to steroids. Gene 530:201\u2013207","journal-title":"Gene"},{"key":"3929_CR85","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1093\/ndt\/gfr150","volume":"26","author":"T Jafar","year":"2011","unstructured":"Jafar T, Prasad N, Agarwal V, Mahdi A, Gupta A, Sharma RK, Negi MP, Agrawal S (2011) MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 26:3968\u20133974","journal-title":"Nephrol Dial Transplant"},{"key":"3929_CR86","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/09674845.2016.1220707","volume":"74","author":"MA Safan","year":"2017","unstructured":"Safan MA, Elhelbawy NG, Midan DA, Khader HF (2017) ABCB1 polymorphisms and steroid treatment in children with idiopathic nephrotic syndrome. Br J Biomed Sci 74:36\u201341","journal-title":"Br J Biomed Sci"},{"key":"3929_CR87","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2217\/pgs-2016-0029","volume":"17","author":"S Turolo","year":"2016","unstructured":"Turolo S, Edefonti A, Lepore M, Ghio L, Cuzzoni E, Decorti G, Pasini A, Materassi M, Malaventura C, Pugliese F, Montini G (2016) SXR rs3842689: a prognostic factor for steroid sensitivity or resistance in pediatric idiopathic nephrotic syndrome. Pharmacogenomics 17:1227\u20131233","journal-title":"Pharmacogenomics"},{"key":"3929_CR88","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1210\/rp.59.1.333","volume":"59","author":"EF Rossum van","year":"2004","unstructured":"van Rossum EF, Lamberts SW (2004) Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog Horm Res 59:333\u2013357","journal-title":"Recent Prog Horm Res"},{"key":"3929_CR89","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3748\/wjg.v17.i9.1095","volume":"17","author":"S Iudicibus De","year":"2011","unstructured":"De Iudicibus S, Franca R, Martelossi S, Ventura A, Decorti G (2011) Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol 17:1095\u20131108","journal-title":"World J Gastroenterol"},{"key":"3929_CR90","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/MPH.0000000000000535","volume":"38","author":"O Eipel","year":"2016","unstructured":"Eipel O, Hegyi M, Csordas K, Nemeth K, Luczay A, Torok D, Csoka M, Erdelyi D, Kovacs G (2016) Some GCR polymorphisms (N363S, ER22\/23EK, and Bcl-1) may influence steroid-induced toxicities and survival rates in children with ALL. J Pediatr Hematol Oncol 38:334\u2013340","journal-title":"J Pediatr Hematol Oncol"},{"key":"3929_CR91","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12185-012-1236-1","volume":"97","author":"OT Eipel","year":"2013","unstructured":"Eipel OT, Nemeth K, Torok D, Csordas K, Hegyi M, Ponyi A, Ferenczy A, Erdelyi DJ, Csoka M, Kovacs GT (2013) The glucocorticoid receptor gene polymorphism N363S predisposes to more severe toxic side effects during pediatric acute lymphoblastic leukemia (ALL) therapy. Int J Hematol 97:216\u2013222","journal-title":"Int J Hematol"},{"key":"3929_CR92","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbrc.2006.07.097","volume":"348","author":"J Ye","year":"2006","unstructured":"Ye J, Yu Z, Ding J, Chen Y, Huang J, Yao Y, Xiao H, Yang J, Shen Y, Meng Q (2006) Genetic variations of the NR3C1 gene in children with sporadic nephrotic syndrome. Biochem Biophys Res Commun 348:507\u2013513","journal-title":"Biochem Biophys Res Commun"},{"key":"3929_CR93","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3345\/kjp.2009.52.11.1260","volume":"52","author":"HY Cho","year":"2009","unstructured":"Cho HY, Choi HJ, Lee SL, Lee HK, Kang HK, Ha IS, Choi Y, Cheong HI (2009) Polymorphisms of the NR3C1 gene in Korean children with nephrotic syndrome. Korean J Pediatr 52:1260\u20131266","journal-title":"Korean J Pediatr"},{"key":"3929_CR94","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.intimp.2012.08.012","volume":"14","author":"J Ouyang","year":"2012","unstructured":"Ouyang J, Chen P, Jiang T, Chen Y, Li J (2012) Nuclear HSP90 regulates the glucocorticoid responsiveness of PBMCs in patients with idiopathic nephrotic syndrome. Int Immunopharmacol 14:334\u2013340","journal-title":"Int Immunopharmacol"},{"key":"3929_CR95","first-page":"1051","volume":"114","author":"X Qian","year":"2001","unstructured":"Qian X, Zhu Y, Xu W, Lin Y (2001) Glucocorticoid receptor and heat shock protein 90 in peripheral blood mononuclear cells from asthmatics. Chin Med J 114:1051\u20131054","journal-title":"Chin Med J"},{"key":"3929_CR96","first-page":"994","volume":"10","author":"S Kojika","year":"1996","unstructured":"Kojika S, Sugita K, Inukai T, Saito M, Iijima K, Tezuka T, Goi K, Shiraishi K, Mori T, Okazaki T, Kagami K, Ohyama K, Nakazawa S (1996) Mechanisms of glucocorticoid resistance in human leukemic cells: implication of abnormal 90 and 70 kDa heat shock proteins. Leukemia 10:994\u2013999","journal-title":"Leukemia"},{"key":"3929_CR97","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/tpj.2011.26","volume":"12","author":"P Maltese","year":"2012","unstructured":"Maltese P, Palma L, Sfara C, de Rocco P, Latiano A, Palmieri O, Corritore G, Annese V, Magnani M (2012) Glucocorticoid resistance in Crohn\u2019s disease and ulcerative colitis: an association study investigating GR and FKBP5 gene polymorphisms. Pharmacogenomics J 12:432\u2013438","journal-title":"Pharmacogenomics J"},{"key":"3929_CR98","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1465-9921-10-67","volume":"10","author":"BA Raby","year":"2009","unstructured":"Raby BA, Van Steen K, Lasky-Su J, Tantisira K, Kaplan F, Weiss ST (2009) Importin-13 genetic variation is associated with improved airway responsiveness in childhood asthma. Respir Res 10:67","journal-title":"Respir Res"},{"key":"3929_CR99","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0022-3476(73)80367-1","volume":"83","author":"T Groshong","year":"1973","unstructured":"Groshong T, Mendelson L, Mendoza S, Bazaral M, Hamburger R, Tune B (1973) Serum IgE in patients with minimal-change nephrotic syndrome. J Pediatr 83:767\u2013771","journal-title":"J Pediatr"},{"key":"3929_CR100","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1056\/NEJM199712113372403","volume":"337","author":"GK Hershey","year":"1997","unstructured":"Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA (1997) The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med 337:1720\u20131725","journal-title":"N Engl J Med"},{"key":"3929_CR101","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1042\/cs1020507","volume":"102","author":"K Tenbrock","year":"2002","unstructured":"Tenbrock K, Schubert A, Stapenhorst L, Kemper MJ, Gellermann J, Timmermann K, M\u00fcller-Wiefel DE, Querfeld U, Hoppe B, Michalk D (2002) Type I IgE receptor, interleukin 4 receptor and interleukin 13 polymorphisms in children with nephrotic syndrome. Clin Sci (Lond) 102:507\u2013512","journal-title":"Clin Sci (Lond)"},{"key":"3929_CR102","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1042\/cs0960665","volume":"96","author":"RG Parry","year":"1999","unstructured":"Parry RG, Gillespie KM, Parnham A, Clark AG, Mathieson PW (1999) Interleukin-4 and interleukin-4 receptor polymorphisms in minimal change nephropathy. Clin Sci (Lond) 96:665\u2013668","journal-title":"Clin Sci (Lond)"},{"key":"3929_CR103","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ndt\/gfh648","volume":"20","author":"CL Wei","year":"2005","unstructured":"Wei CL, Cheung W, Heng CK, Arty N, Chong SS, Lee BW, Puah KL, Yap HK (2005) Interleukin-13 genetic polymorphisms in Singapore Chinese children correlate with long-term outcome of minimal-change disease. Nephrol Dial Transplant 20:728\u2013734","journal-title":"Nephrol Dial Transplant"},{"key":"3929_CR104","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00467-011-1903-0","volume":"26","author":"HJ Choi","year":"2011","unstructured":"Choi HJ, Cho HY, Ro H, Lee SH, Han KH, Lee HK, Kang HG, Ha SI, Choi Y, Cheong HI (2011) Polymorphisms of the MDR1 and MIF genes in children with nephrotic syndrome. Pediatr Nephrol 26:1981\u20131988","journal-title":"Pediatr Nephrol"},{"key":"3929_CR105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.18388\/abp.2014_1925","volume":"61","author":"M Swierczewska","year":"2014","unstructured":"Swierczewska M, Ostalska-Nowicka D, Kempisty B, Szczepankiewicz A, Nowicki M (2014) Polymorphic variants of MIF gene and prognosis in steroid therapy in children with idiopathic nephrotic syndrome. Acta Biochim Pol 61:67\u201375","journal-title":"Acta Biochim Pol"},{"key":"3929_CR106","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/nep.12353","volume":"20","author":"X Tong","year":"2015","unstructured":"Tong X, He J, Liu S, Peng S, Yan Z, Zhang Y, Fan H (2015) Macrophage migration inhibitory factor -173G\/C gene polymorphism increases the risk of renal disease: a meta-analysis. Nephrology (Carlton) 20:68\u201376","journal-title":"Nephrology (Carlton)"},{"key":"3929_CR107","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1523-1755.2004.00394.x","volume":"65","author":"S Sasaki","year":"2004","unstructured":"Sasaki S, Nishihira J, Ishibashi T, Yamasaki Y, Obikane K, Echigoya M, Sado Y, Ninomiya Y, Kobayashi K (2004) Transgene of MIF induces podocyte injury and progressive mesangial sclerosis in the mouse kidney. Kidney Int 65:469\u2013481","journal-title":"Kidney Int"},{"key":"3929_CR108","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0272-6386(12)80742-6","volume":"21","author":"MG Suranyi","year":"1993","unstructured":"Suranyi MG, Guasch A, Hall BM, Myers BD (1993) Elevated levels of tumor necrosis factor-alpha in the nephrotic syndrome in humans. Am J Kidney Dis 21:251\u2013259","journal-title":"Am J Kidney Dis"},{"key":"3929_CR109","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1365-2362.1994.tb02022.x","volume":"24","author":"C Bustos","year":"1994","unstructured":"Bustos C, Gonzalez E, Muley R, Alonso JL, Egido J (1994) Increase of tumour necrosis factor alpha synthesis and gene expression in peripheral blood mononuclear cells of children with idiopathic nephrotic syndrome. Eur J Clin Investig 24:799\u2013805","journal-title":"Eur J Clin Investig"},{"key":"3929_CR110","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00467-003-1403-y","volume":"19","author":"SD Kim","year":"2004","unstructured":"Kim SD, Park JM, Kim IS, Choi KD, Lee BC, Lee SH, Hong SJ, Jin SY, Lee HJ, Hong MS, Chung JH, Lee TW, Ihm CG, Cho BS (2004) Association of IL-1beta, IL-1ra, and TNF-alpha gene polymorphisms in childhood nephrotic syndrome. Pediatr Nephrol 19:295\u2013299","journal-title":"Pediatr Nephrol"},{"key":"3929_CR111","first-page":"164","volume":"12","author":"I Tieranu","year":"2017","unstructured":"Tieranu I, Dutescu MI, Bara C, Tieranu CG, Balgradean M, Popa OM (2017) Preliminary study regarding the association between tumor necrosis factor alpha gene polymorphisms and childhood idiopathic nephrotic syndrome in Romanian pediatric patients. Maedica (Buchar) 12:164\u2013168","journal-title":"Maedica (Buchar)"},{"key":"3929_CR112","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0303-7207(95)03481-L","volume":"108","author":"MS Chapman","year":"1995","unstructured":"Chapman MS, Qu N, Pascoe S, Chen WX, Apostol C, Gordon D, Miesfeld RL (1995) Isolation of differentially expressed sequence tags from steroid-responsive cells using mRNA differential display. Mol Cell Endocrinol 108:R1\u2013R7","journal-title":"Mol Cell Endocrinol"},{"key":"3929_CR113","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJMoa0911353","volume":"365","author":"KG Tantisira","year":"2011","unstructured":"Tantisira KG, Lasky-Su J, Harada M, Murphy A, Litonjua AA, Himes BE, Lange C, Lazarus R, Sylvia J, Klanderman B, Duan QL, Qiu W, Hirota T, Martinez FD, Mauger D, Sorkness C, Szefler S, Lazarus SC, Lemanske RF Jr, Peters SP, Lima JJ, Nakamura Y, Tamari M, Weiss ST (2011) Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 365:1173\u20131183","journal-title":"N Engl J Med"},{"key":"3929_CR114","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00467-012-2197-6","volume":"27","author":"HI Cheong","year":"2012","unstructured":"Cheong HI, Kang HG, Schlondorff J (2012) GLCCI1 single nucleotide polymorphisms in pediatric nephrotic syndrome. Pediatr Nephrol 27:1595\u20131599","journal-title":"Pediatr Nephrol"},{"key":"3929_CR115","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1677\/joe.0.1750251","volume":"175","author":"AM Karssen","year":"2002","unstructured":"Karssen AM, Meijer OC, van der Sandt IC, De Boer AG, De Lange EC, De Kloet ER (2002) The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol 175:251\u2013260","journal-title":"J Endocrinol"},{"key":"3929_CR116","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1007\/s00467-006-0187-2","volume":"21","author":"A Wasilewska","year":"2006","unstructured":"Wasilewska A, Zoch-Zwierz W, Pietruczuk M, Zalewski G (2006) Expression of P-glycoprotein in lymphocytes from children with nephrotic syndrome, depending on their steroid response. Pediatr Nephrol 21:1274\u20131280","journal-title":"Pediatr Nephrol"},{"key":"3929_CR117","first-page":"218","volume":"8","author":"J Stachowski","year":"2000","unstructured":"Stachowski J, Zanker CB, Runowski D, Zaniew M, Peszko A, Medynska A, Zwolinska D, Rogowska-Kalisz A, Hyla-Klekot L, Szprygner K, Weglarska J, Sieniawska M, Musial W, Maciejewski J, Baldamus CA (2000) Resistance to therapy in primary nephrotic syndrome: effect of MDR1 gene activity. [Polish] (Odpornosc na leczenie w przebiegu pierwotnego zespolu nerczycowego: wplyw aktywnosci genu MDR1.) Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego 8:218\u2013221","journal-title":"Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego"},{"key":"3929_CR118","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1517\/phgs.4.4.397.22747","volume":"4","author":"T Sakaeda","year":"2003","unstructured":"Sakaeda T, Nakamura T, Okumura K (2003) Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4:397\u2013410","journal-title":"Pharmacogenomics"},{"key":"3929_CR119","doi-asserted-by":"publisher","unstructured":"Conyers R, Devaraja S, Elliott D (2017) Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.26937","DOI":"10.1002\/pbc.26937"},{"key":"3929_CR120","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1089\/gtmb.2015.0077","volume":"19","author":"MC Dhandapani","year":"2015","unstructured":"Dhandapani MC, Venkatesan V, Rengaswamy NB, Gowrishankar K, Nageswaran P, Perumal V (2015) Association of ACE and MDR1 gene polymorphisms with steroid resistance in children with idiopathic nephrotic syndrome. Genet Test Mol Biomarkers 19:454\u2013456","journal-title":"Genet Test Mol Biomarkers"},{"key":"3929_CR121","doi-asserted-by":"crossref","first-page":"59","DOI":"10.12659\/MSM.891366","volume":"21","author":"M Cizmarikova","year":"2015","unstructured":"Cizmarikova M, Podracka L, Klimcakova L, Habalova V, Boor A, Mojzis J, Mirossay L (2015) MDR1 polymorphisms and idiopathic nephrotic syndrome in Slovak children: preliminary results. Med Sci Monit 21:59\u201368","journal-title":"Med Sci Monit"},{"key":"3929_CR122","volume":"96","author":"SS Han","year":"2017","unstructured":"Han SS, Xu YQ, Lu Y, Gu XC, Wang Y (2017) A PRISMA-compliant meta-analysis of MDR1 polymorphisms and idiopathic nephrotic syndrome: susceptibility and steroid responsiveness. Medicine (Baltimore) 96:e7191","journal-title":"Medicine (Baltimore)"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-3929-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-3929-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-3929-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T04:57:03Z","timestamp":1660625823000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-3929-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,16]]},"references-count":122,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["3929"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-3929-z","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,16]]},"assertion":[{"value":"20 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}